Cautious Approach Needed to HTPs' Harm Reduction Claims: Study

Nov.11.2022
Cautious Approach Needed to HTPs' Harm Reduction Claims: Study
A new study warns that current evidence on heated tobacco products (HTPs) doesn't meet standards, and claims of harm reduction should be taken with caution.

The author of a new study published in "Tobacco Control" has stated that the quality of existing evidence regarding heated tobacco products (HTPs) is insufficient and policymakers should be cautious about claims of harm reduction.


In recent years, HTPs have become popular and supporters insist that they pose less harm to health than traditional cigarettes. However, researchers from the University of Bath argue that the evidence supporting these claims largely fails to account for real-world usage and is subject to a high risk of bias.


In their analysis of 40 publicly disclosed HTP clinical trials, 29 of which were affiliated with or sponsored by the tobacco industry, researchers determined that the majority of existing clinical trials have a "high risk of bias" based on their methods and study design.


The most common reason for research to be at high risk of bias is performance bias, which occurs when participants and those conducting the test are aware of the intervention measures being assigned. Additionally, failure to report all result data from the trial measurements is a flaw known as selective reporting bias.


The author believes that the existence of biases has damaged the validity of the experiment, which may lead to an overestimation of the effectiveness of HTP. They also found further limitations in the experiment, including a short duration, restrictive conditions that do not reflect real-world situations, and a lack of relevant comparators, such as e-cigarettes.


The tobacco control research group in Bath says that more detailed independent studies are necessary to evaluate the short and long-term health effects of HTPs.


At the same time, they believe that consumers should be wary of claims of harm reduction, and policymakers and regulators should carefully consider the role of these trials when making decisions surrounding HTPs.


In recent years, there has been significant development in the heated tobacco market in the UK and around the world. According to Sophie Braznell, Chief Researcher at Bath Health Authority, this growth is premised on the notion that these products are healthier than traditional cigarettes.


Our analysis indicates that the situation is far from clear. Clinical trials used by the tobacco industry to support these claims are often inadequate in terms of research methods and reporting, and most are somehow linked to the tobacco industry.


As more and more consumers are turning away from cigarettes and towards these new generation products, there is a need for better evidence to evaluate their current and future health impact. At the same time, the jury is still out on their potential benefits.


The findings related to clinical trials on heated tobacco products are very important, and we need to remain vigilant about the health claims made," added Gemma Taylor, a co-author of the research report from the Addiction and Mental Health Group and Department of Psychology at the University of Bath.


However, at the same time, it is important to note the clear distinction between "heated tobacco products" and "electronic cigarettes". Consumers and health policy makers must not equate the potential benefits of electronic cigarettes in helping people quit smoking with heated tobacco products.


Statement:


This article is compiled from third-party information and is only intended for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The translation of this article is solely for the purpose of industry exchange and research.


Due to limitations in the translation skills, the translated article may differ from the original text. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on all statements and positions related to domestic issues, as well as those involving Hong Kong, Macau, Taiwan, and foreign affairs.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Philippine Tobacco Control Coalition Backs Raising Legal Age for Vape and Tobacco Products to 25
Philippine Tobacco Control Coalition Backs Raising Legal Age for Vape and Tobacco Products to 25
A coalition of health and child rights advocates in the Philippines said it supports Health Secretary Teodoro Herbosa’s call to raise the legal age restriction for vape and tobacco products from 18 to 25. The group said scientific evidence shows that the brain of a young person continues to develop until the mid-20s, and that nicotine exposure during that period can cause lasting impairment in impulse control, learning, and mood regulation.
Mar.11 by 2FIRSTS.ai
Special Report | 71 U.S. Lawmakers Seek to Elevate Illicit Vape Crackdown to U.S.–China Trade Negotiations
Special Report | 71 U.S. Lawmakers Seek to Elevate Illicit Vape Crackdown to U.S.–China Trade Negotiations
U.S. Rep.Mike Carey and 70 other Republican lawmakers have urged federal officials to elevate the crackdown on illicit vapes to the U.S.–China trade agenda. In a March 4 letter to the Treasury Secretary and the U.S. Trade Representative, they warned that unauthorized vape products pose risks related to national security, youth protection and organized crime. The signatories represent about one-third of House Republicans, highlighting growing congressional attention to illicit vape trade.
Mar.10
Product | Refillable up to 30 mL in total and claimed 60,000 puffs: MASKKING launches open-system UCEE MAX
Product | Refillable up to 30 mL in total and claimed 60,000 puffs: MASKKING launches open-system UCEE MAX
E-cigarette brand MASKKING has recently listed its new UCEE MAX on its official website. According to the website, the device features an open, refillable design with a stated 10 mL e-liquid capacity, supports three refills, and claims a total of 60,000 puffs.
Mar.02 by 2FIRSTS.ai
Malaysia moves ahead with vape sales ban plan; PMI urges Japan-style differentiated excise taxes
Malaysia moves ahead with vape sales ban plan; PMI urges Japan-style differentiated excise taxes
Malaysia plans to implement a ban or restrictions on e-cigarettes and vaping products as early as mid-2026 and no later than year-end. The head of Philip Morris Malaysia and Singapore said the government should look to Japan’s approach of regulating and taxing different tobacco and nicotine products differently, warning that an outright ban could push demand into illicit channels.
Feb.02
Reuters/AP: China Cancels E-cigarette Export Tax Rebate, Manufacturing Industry Faces Cost and Risk Pressures
Reuters/AP: China Cancels E-cigarette Export Tax Rebate, Manufacturing Industry Faces Cost and Risk Pressures
China officially cancels e-cigarette export tax rebate, putting manufacturing under cost and risk pressure.
Jan.16 by 2FIRSTS.ai
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
At the opening of FDA’s PMTA roundtable, small ENDS manufacturers warned that unclear product characterization standards are limiting their ability to invest and raise capital. FDA officials acknowledged industry concerns but said regulatory flexibility is constrained by statutory and procedural boundaries.
Feb.11